Bayer close to closing buyout of Algeta; KV forms two divisions; Alchemia gets new CEO;

@FierceBiotech: Assessing the crowd effect on biopharma's risky R&D strategy. More | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers picks up another "breakthrough" trophy in hep C cocktail showdown. News | Follow @JohnCFierce

@DamianFierce: As Big Pharma sells/spins out its animal health ops, Lily buys one. Release | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story | Follow @EmilyMFierce

> Bayer is wrapping up its $2.9 billion deal to acquire Norway's Algeta. Story

> The FDA has pushed back the PDUFA date on Salix Pharmaceuticals' ($SLXP) Ruconest for hereditary angioedema by three months. Release

> KV Pharmaceutical ($KV.A) has created two new divisions under its reorganization. Story

> Just a year after his appointment, Brisbane-based Alchemia CEO Charles Walker has left the company. He's being replaced by Thomas Liquard. Report

Medical Device News

@FierceMedDev: German study backs a Japanese firm's dissolving stent over the bare metal variety. Story | Follow @FierceMedDev

@MichaelGFierce: Capsule Tech launches a medical device integration system with a few big partners. More | Follow @MichaelGFierce

@EmilyWFierce: 3-D printing technology could be used to construct human organs, say scientists. Article | Follow @EmilyWFierce

@GalenMoore: Startup Constant Therapy raises seed funds for its iPad-based brain injury treatment. More | Follow @GalenMoore

> Endo is stocking up at least $520M to cover vaginal mesh lawsuit legal costs. Story

> Boston Scientific partners up to push Parkinson's tech in Europe. Article

Pharma News

@FiercePharma: With Teva's Symbicort copy nearing EU launch, AstraZeneca preps for battle. Story | Follow @FiercePharma

@TracyStaton: Top story at FiercePharma over weekend: FDA moves toward major overhaul in the way it approves OTC meds. More | Follow @TracyStaton

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Report | Follow @EricPFierce

@CarlyHFierce: Vertex eyes another $45 million in sales as FDA swells Kalydeco's patient pool. News | Follow @CarlyHFierce

> Will the generics M&A surge put Teva on the takeover table? Investors think so. Article

> Pfizer closes in on $1B-plus sales boost for Prevnar 13 vaccine. Story

> The FDA is quietly testing some drugs for generic equivalency. Piece

CRO News

> Medpace changes hands for $915M as private equity smiles on CROs. News

> After soaring 20% in 2013, Icon eyes a bigger share of the CRO market. Article

> Quintiles lends its sequencing skills to massive cardiovascular study. Story

> Parexel expands its regulatory reach with latest move. News

> PPD partners up to give Germany a starring role in clinical trials. Story

> Charles River amps up its biologics testing. Item

Biotech IT News

> Buzz: BGI is preparing for a $400M Hong Kong IPO in Q4. Report

> U.K. delays patient database project following public backlash. News

> Roche mulls sharing Avastin trial data to clear up possible statistical quirk. Story

> U.S. team taps supercomputer to accelerate genome data analysis. Article

> Merge prepares to defend itself against fake contract lawsuits. News

> Pfizer CEO begins contributing to LinkedIn's publishing platform. Brief

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.